Background-Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Individually, NOACs were at least noninferior to vitamin K antagonists, but a clear superiority in overall and vascular mortality was not consistently proven. Methods and Results-We performed a meta-analysis of phase II and phase III randomized, controlled trials comparing NOACs with vitamin K antagonists in patients with atrial fibrillation. The MEDLINE and EMBASE databases, supplemented with conference abstract books and www.clinicaltrials.gov, were searched up to the first week of July 2012 with no language restriction. Two reviewers performed independent article review and study quality assessment. Data on overall and cardiovascular mortality, stroke or systemic embolism, ischemic stroke, major and intracranial bleeding, and myocardial infarction were collected. NOACs were pooled to perform a comparison with vitamin K antagonists, calculating pooled relative risks (RRs) and associated 95% confidence intervals (CIs). We retrieved 12 studies (3 administering dabigatran, 4 administering rivaroxaban, 2 administering apixaban, and 3 administering edoxaban) enrolling a total of 54 875 patients. NOACs significantly reduced total mortality (5.61% versus 6.02%; RR, 0.89; 95% CI, 0.83-0.96), cardiovascular mortality (3.45% versus 3.65%; RR, 0.89; 95% CI, 0.82-0.98), and stroke/systemic embolism (2.40% versus 3.13%; RR, 0.77; 95% CI, 0.70 -0.86). There was a trend toward reduced major bleeding (RR, 0.86; 95% CI, 0.72-1.02) with a significant reduction of intracranial hemorrhage (RR, 0.46; 95% CI, 0.39 -0.56). No difference in myocardial infarction was observed. Conclusions-NOACs are associated with an overall clinical benefit compared with vitamin K antagonists. Additional research is required to confirm these findings outside the context of randomized trials.
A trial fibrillation (AF) is the most common cardiac arrhythmia, with an overall prevalence of 5.5% that increases up to 17.8% in individuals Ն85 years of age. 1 AF is a major risk factor for stroke, 2 with a 30-day mortality rate of 24% in the absence of treatment. 3 
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Vitamin K antagonists (VKAs) are highly effective for the prevention of stroke, mainly of ischemic origin, in patients with AF, resulting in a 64% risk reduction compared with placebo and a 37% risk reduction compared with antiplatelet therapy. 4 For this reason, VKAs are currently recommended in all AF patients at moderate to high risk for stroke or systemic embolism (SE). 5 However, VKAs have significant limitations, particularly their unpredictable anticoagulant response and numerous food and drug interactions, mandating regular laboratory monitoring. 6 These limitations make treatment with VKAs problematic for many patients; as a result, only about half of all potentially eligible AF patients are treated with VKAs. 6 Over the last several years, novel oral anticoagulant drugs (NOACs), including direct thrombin inhibitors and factor Xa inhibitors, have been developed. These drugs have the potential to address some of the limitations of VKAs. 7 These agents have fewer food and drug interactions and a more predictable anticoagulant effect, thus allowing fixed dosing without the need for laboratory monitoring. Furthermore, their shorter half-life may produce additional advantages, eg, if temporary interruption is required for a surgical procedure or in the case of an hemorrhagic complication.
The NOACs have been compared with warfarin for the prevention of stroke and SE in patients with AF. 8 -10 These trials have been favorable for the NOACs but have not consistently demonstrated superiority over warfarin, particularly in terms of overall and vascular mortality. To better assess the clinical benefit, we carried out a systematic review of the literature and a meta-analysis of phase II and phase III randomized, clinical trials (RCTs) of these agents compared with VKAs for the prevention of stroke or SE in patients with AF.
Methods
A protocol for this review was prospectively developed that detailed the specific objectives, criteria for study selection, approach to assess study quality, outcomes, and statistical methods. This protocol is available for review through the investigators.
Data Sources and Searches
We identified all published studies that compared the risk of thromboembolic and/or major bleeding (MB) events in AF patients randomized to VKAs (warfarin, phenprocoumon, acenocumarol, fluindione, and tecarfarin) or NOACs (dabigatran, AZD0837, sofigatran, rivaroxaban, apixaban, edoxaban, betrixaban, eribaxaban, LY517717, YM150, TAK442, and TTP889) using the MEDLINE (1966 to week 1 of July 2012) and the EMBASE (1980 to week 1 of July 2012) electronic databases. The term ximelagatran was excluded from the search because this drug has been withdrawn from the market. The search strategy was developed without any language restriction and used the medical subject headings and text words presented in Table 1 in the online-only Data Supplement. We supplemented our search by reviewing abstracts books from the congresses of the International Society on Thrombosis and Haemostasis 
Study Selection
Two reviewers (N.R. and F.D.) performed study selection independently, with disagreements solved through discussion and by the opinion of a third reviewer (W.A.) if necessary. Studies were considered potentially eligible for this systematic review if they met the following criteria: They were phase III RCTs or phase II RCTs including at least one of the evaluated dosages subsequently used in phase III trials; NOACs were compared with therapeutic doses of VKAs in patients with AF; and thromboembolic and bleeding events were objectively assessed in both groups.
For trials that were reported in Ͼ1 publication, we extracted data from the most complete publication and used other publications to clarify data.
To assess the agreement between reviewers for study selection, we used the statistic, which measures agreement beyond chance. 11
Data Extraction and Quality Assessment
We extracted and presented data according to the Providing Innovative Service Models and Assessment (PRISMA) criteria. 12 Two reviewers (N.R. and F.D.) independently extracted data on study (year of publication, design), population characteristics (number of patients, mean age, sex), and treatment (therapeutic indication, type of drug, dose, and duration).
Information on the following outcomes was collected in the 2 groups: number of total and ischemic strokes (ISs), SE, total and cardiovascular mortality, MB and intracranial bleeding, and myocardial infarctions (MIs). No attempt was made to reclassify bleeding events. However, in the included studies, MBs were classified mostly according to International Society on Thrombosis and Haemostasis criteria 13 as bleeding causing a fall in hemoglobin levels of Ն2 g/dL, bleeding leading to transfusion of Ն2 U whole blood or red cells, symptomatic bleeding in a critical area (intracranial, intraspinal, intraocular, retroperitoneal, intrarticular, pericardial, or intramuscular with compartment syndrome), or bleeding events leading to death.
If outcome data for extraction could not be identified, we contacted the study authors by e-mail, with a reminder after 15 days. For unpublished trials, we also contacted the pharmaceutical companies.
Two reviewers (N.R. and F.D.) independently assessed study quality using a validated scale 14 based on the following criteria: methods used to generate the randomization sequence, method of double blinding, and description of patient withdrawals and dropouts. A score of 1 point was given for each criterion satisfied, and 1 additional point was given for high quality of randomization and double blinding, for a maximum of 5 points. Studies with a score Ͼ2 were considered high quality, and studies with a score Յ2 were considered low quality. Although concealed treatment allocation is not part of this rating scale, it was included in our study quality assessment.
We resolved disagreements about study data extraction by consensus or by discussion with a third reviewer (W.A.).
Statistical Analyses

Primary Analyses
We determined pooled relative risks (RRs) and corresponding 95% confidence intervals (CIs) for all-cause and cardiovascular mortality in AF patients who received VKAs or treatment with a NOAC. Furthermore, the pooled RR of any cardioembolic event (which included stroke or SE), IS, MB and intracranial bleeding, and MI in the 2 arms of treatment was calculated. Because transient ischemic attacks are frequently subjective, seldom consistently reported, and not usually considered a primary outcome in AF trials, we decided not to include them in our analysis.
Although we acknowledge that direct thrombin inhibitors and factor Xa inhibitors have different pharmacodynamic and pharmacokinetic properties, they all act on the final phase of the coagulation cascade, the common pathway, and represent as a whole the current alternative to VKAs. For this reason, we considered it appropriate to pool the NOACs together to perform a comparison with VKAs.
From phase II dose-ranging RCTs, we summed all groups whose total daily dose was equal to the regimens used in phase III RCTs. For all the treatment effects that were statistically significant, we determined the absolute risk reduction (ARR) or the absolute risk increase and the corresponding number needed to treat (NNT) or number needed to harm. Data were pooled by use of a fixed-effects model (Mantel-Haenszel method), 15 and results were compared with the results obtained with a random-effects (RE) model (DerSimonian-Laird method). 16 A value of PϽ0.05 was considered statistically significant. All analyses were performed with ReviewManager software (RevMan, version 5.1.6 for Windows; The Cochrane Collaboration, Oxford, UK; 2008). Because combining trials with extremely low or zero event rates can yield biased results, we repeated the analyses using Comprehensive Meta-Analysis software, version 2 (Biostat Software Corp, Englewood, NJ), which provides exact fixed-effect point and interval estimates for the odds ratio. 17 The appropriateness of pooling data across studies was assessed with the use of the Cochran Q and the I 2 test for heterogeneity, which measures the inconsistency across study results and describes the proportion of total variation in study estimates that is due to heterogeneity rather than sampling error. 18 For the preparation of the forest plots, we also used the Meta Data Viewer software version 1.02 (National Toxicology Program, Research Triangle Park, NC). 19 The presence of publication bias was investigated by the use of funnel plots of effect size versus standard error. 20 
Sensitivity Analyses
We repeated sensitivity analyses by using only studies that satisfied each item of our prespecified quality evaluation. 21 Furthermore, separate analyses of studies published in peer-reviewed journals were provided.
Subgroup Analyses
We planned to perform separate analyses of studies assessing short-term outcomes (1-3 months) and long-term outcomes (Ͼ1 year).
We also performed separate analyses including, from phase II trials, only the exact same dose regimen of the NOAC that was subsequently used in phase III trials and, in a separate analysis, excluding the lower dosage of dabigatran (110 mg twice daily), which is not licensed by the US Food and Drug Administration.
Results
Study Identification and Selection
We identified 1454 potentially relevant studies: 364 from MEDLINE and 1090 from EMBASE. A total of 317 studies were duplicated, and 1106 studies were excluded after title and abstract screening. The remaining 31 studies were retrieved in full for detailed evaluation. A list of the 24 excluded studies and reasons for exclusion is available on request. Two additional studies were identified from a personal library. 22, 23 We identified 3 more studies by searching unpublished trials on www.clinicaltrials.gov. 24 -26 A review of the reference lists of included studies did not provide any additional references. Twelve studies were therefore included in this systematic review. 8 -10,22-30 Interobserver agreement for study selection was almost perfect (ϭ0.89). The study identification and selection progression are summarized in Figure I in the online-only Data Supplement.
Data from 2 studies were supplemented with information extracted from more recent publications. 31, 32 Supplementary data for 7 trials were provided by the investigators involved in the trial or the pharmaceutical companies. [22] [23] [24] [25] [26] [27] 29 Data on dabigatran and rivaroxaban were also supplemented with information from their Food and Drug Administration reviews. 33, 34 
Study Characteristics and Study Quality
Baseline characteristics of patients included in the studies are summarized in the Table. For 4 NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban), a phase III RCT was published or was ongoing. The comparator VKA was warfarin in all studies. All studies were published in English. Study size ranged from 100 patients 26 to 18 201 patients, 10 for a total of 54 875 included patients. Eight studies were phase II RCTs 22,24 -30 and 4 studies were phase III RCTs. 8 -10,23 Three studies involved dabigatran, 8, 24, 30 4 involved rivaroxaban, 9,23,25,26 2 involved apixaban, 10,27 and 3 involved edoxaban. 22, 28, 29 Quality assessment items are summarized in Table II in the online-only Data Supplement. With the use of the Jadad score, 6 studies were classified as low quality 22,24 -27,30 and 6 as high quality. 8 -10,23,28,29 All the trials were randomized, but the method to generate the randomization sequence was adequately reported in 4 studies. Three studies were doubleblind and double-dummy. All studies provided a description of patient withdrawals, and 6 reported concealed treatment allocation. Table III in the online-only Data Supplement summarizes the outcomes assessed during oral anticoagulant treatment. When possible, we performed analyses using intention-to-treat populations. The intention-to-treat populations were not available for all outcomes for 2 studies 9,23 ; therefore, we used the safety-on-treatment populations.
Outcomes
Primary Analyses
Total Mortality
Death occurred in 1715 of 30 584 patients (5.61%) treated with NOACs and in 1416 of 23 531 patients (6.02%) treated with VKAs ( Figure 1A) Figure 2B ). Use of NOACs was associated with a nonsignificant reduction in the number of ISs (RR, 0.92; 95% CI, 0.81-1.04; I 2 ϭ22%). Reanalysis with an RE model did not change these results.
MB and Intracranial Bleeding
The definition of MB and the proportion of patients taking VKAs before inclusion and/or taking concomitant aspirin during the trial were not declared in many studies and were variable in the others (the Table) .
MB, as defined by the study, occurred in 1498 of 30 599 patients (4.90%) treated with NOACs and in 1304 of 23 548 patients (5.54%) treated with VKAs ( Figure 3A) . Use of NOACs was associated with a significant reduction in the rate of MB events (RR, 0.86; 95% CI, 0.80 -0.93; ARR, 0.64%; I 2 ϭ57%; NNT, 157). Reanalysis using an RE model demonstrated a trend toward a reduction in MB (RR, 0.86; 95% CI, 0.72-1.02). Given the significant heterogeneity (PϽ0.05), we performed a subgroup analysis examining each NOAC (Figure II in the online-only Data Supplement). In this analysis, apixaban and dabigatran reduced MB events, whereas neither rivaroxaban nor edoxaban reduced bleeding. For the CHADS 2 score, 1 point is given for cardiac heart failure, hypertension, age Ն75 years, and diabetes mellitus; 2 points are given for previous stroke, transient ischemic attack, and systemic embolism.
*When the characteristics of randomized patients were not available, we reported the characteristics of patients actually treated (studies in References 22-24, 28 -29).
†TTR was calculated in all studies according to the Rosendaal method but using different time frames. ‡See the text for the ISTH definition of major bleeding.
Intracranial bleeding occurred in 180 of 30 599 patients (0.59%) treated with NOACs and in 307 of 23 548 patients (1.30%) treated with VKAs ( Figure 3B ). Use of NOACs was associated with a significant reduction in the risk of intracranial bleeding events (RR, 0.46; 95% CI, 0.39 -0.56; I 2 ϭ34%; ARR, 0.71%; NNT, 141). Reanalysis with an RE model did not change these results.
Myocardial Infarction
MI occurred in 394 of 30 584 patients (1.29%) treated with NOACs and in 304 of 23 531 patients (1.29%) treated with VKAs ( Figure 4 ). There was no difference in the risk of developing MI between NOACs and VKAs (RR, 0.99; 95% CI, 0.85-1.15; I 2 ϭ55%). Reanalysis using an RE model did not show significant changes in the results (RR, 1.00; 95% CI, 0.75-1.33). Given the high level of heterogeneity, we performed a subgroup analysis separately to assess each novel drug, but we did not find any statistically significant difference between the NOACs and VKAs ( Figure III in the online-only Data Supplement).
Sensitivity Analyses
Sensitivity analyses including only high-quality 8 Similarly, repeating our analyses with Comprehensive Meta Analysis software including trials with extremely low or zero event rates did not change the results of the primary analyses (results available on request). 
Subgroup Analyses
In the subgroup analysis that included only studies with short-term follow-up, 22,24 -30 only the rate of stroke and SE appears to be significantly reduced in patients randomized to NOACs, whereas the rates of cardiovascular and total death, IS, MB, intracranial bleeding, and MI were similar in the 2 groups. In contrast, the subgroup analyses that included only studies with long-term follow-up 8 -10,23 and only the dose regimens used in phase III studies provided the same results as the primary analyses. The analysis excluding the lower dosage of dabigatran showed a reduction of IS with NOACs compared with VKAs (RR, 0.86; 95% CI, 0.76 -0.99; I 2 ϭ30%) using a fixedeffects model. This result was not statistically significant with an RE model (RR, 0.85; 95% CI, 0.70 -1.02; Figures IV-VII in the online-only Data Supplement).
Publication Bias
Funnel plots of effect size versus standard error are summarized in Figures VIII-XI in the online-only Data Supplement. The funnel plot for stroke or SE was asymmetrical with the absence of studies on the right side of the plot, whereas the funnel plot for MI was lacking studies on the left side of the plot. The funnel plots for total mortality and MB appeared symmetrical.
Discussion
This is, to the best of our knowledge, the first systematic review and meta-analysis of phase II and phase III RCTs that compared the NOACs with warfarin for the prevention of stroke and SE in patients with AF. Our analysis, incorporating Ͼ50 000 patients, found a statistically significant 11% RR reduction in the incidence of both total mortality and cardiovascular mortality, which corresponds to an NNT of 244 patients to prevent 1 death and to an NNT of 500 patients to prevent 1 cardiovascular death. The observed advantage of the NOACs is consistent for all outcomes, including stroke and SE reduction (RR reduction, 23%; NNT, 137) and MB reduction (RR reduction, 14%; NNT, 157).
Following the favorable results of the individual clinical trials, dabigatran and rivaroxaban have received approval from the regulatory agencies and apixaban is expected to be licensed in the near future. However, the cost-effectiveness of these compounds remains unclear. This lack of clarity exists, in part, as a result of the observation that single studies have reported small and often nonstatistically significant differences between the NOACs and warfarin for hard end points such as overall mortality and vascular mortality.
We believe that our study could provide more accurate estimates of the expected clinical benefits of the NOACs. Taken together, our results suggest that the use of the NOACs not only provides practical advantages over the VKAs but also is associated with an overall clinical benefit, suggesting their cost-effectiveness.
More important, the NOACs both reduce clinical events and offer the possibility of increasing the use of adequate prophylactic strategies in patients with AF. It is well known that AF remains a major cause of stroke 2 and that the severity of stroke is greater in patients with AF than in other subgroups. 35 Despite this evidence, the use of VKAs in the real world of patients with AF remains unacceptably low, with an overall prevalence of treated high-risk patients not exceeding 70%. 36 The availability of NOACs has the potential to reduce the incidence of AF-related strokes and SE because of both their superior efficacy and their potential to be more widely used compared with the VKAs.
In this meta-analysis, we have combined the results of clinical trials carried out with 4 NOACs. These drugs present some important differences in terms of mechanisms of action; 1 drug (dabigatran etexilate) is a direct thrombin inhibitor and 3 drugs (rivaroxaban, apixaban, and edoxaban) are direct factor Xa inhibitors. Moreover, there are some differences in the mechanisms of excretion, in their mean half-lives, and in the drug-drug interactions, among others. 37 These differences may suggest that combining the results of these drugs may not be appropriate. However, there were no signs of heterogeneity when the outcomes of total and cardiovascular mortality, stroke, or SE were analyzed, thus suggesting that the advantages in terms of efficacy are consistent among all the new agents included in our study. On the other hand, significant heterogeneity was documented when the outcome of MB was analyzed.
This finding may be due in part to some drug-specific or regimen-specific differences in terms of safety, although none of the NOACs were less safe than warfarin, and to patientspecific characteristics. Indeed, some studies enrolled an intermediate-risk population with a mean CHADS 2 score of Ϸ2, 8, 10, 22, [27] [28] [29] whereas other studies enrolled a population at higher risk not only for thromboembolic but also for bleeding complications, with a mean CHADS 2 score Ͼ3. 9, 23 When the analysis was repeated with the exclusion of the lower dose of dabigatran, which is not approved in the United States and is recommended for more fragile patients in other countries, the results were fully comparable to those of the main analysis in terms of total mortality and safety, whereas a tendency toward a greater benefit in the reduction of IS was observed.
There is great interest in the potential increased risk of MI with the use of the NOACs, particularly dabigatran. The results of a recent meta-analysis of trials involving dabigatran for the primary and secondary prevention of cardiovascular diseases found a 33% RR increase in acute coronary events with the novel direct thrombin inhibitors compared with traditional anticoagulant drugs. 38 Another recent analysis comparing warfarin with other antithrombotic drugs (ximelagatran, dabigatran, idraparinux, and clopidogrel) in AF clinical trials found a 23% RR reduction in the rate of MI with warfarin, suggesting the protective effect of the VKA. 39 In this meta-analysis, we failed to detect any difference in the overall risk of MI, with a 1.29% rate in both NOAC-and VKA-treated patients. Of interest, no statistically significant difference was detected after subgroup analysis.
The strengths of this study include the rigorous methodological approach, the selection of all the studies performed with the 4 NOACs considered, and the consistency of the results of sensitivity analyses. Furthermore, to the greatest extent possible, we confined our analysis to clinically relevant events, and because all the studies were performed as a component of product registration, it is likely that all reported outcome events were objectively confirmed.
The study has a number of limitations. First, because this was a study-level meta-analysis, we were unable to confirm the overall results in specific subgroups of patients according to their baseline stroke or bleeding risk. Population characteristics were quite different among the single studies; however, several subgroup analyses have already been published suggesting the consistency of the principal findings across different subgroups such as patients with previous stroke 31,40.41 or more advanced age. 42 Second, we could not compare the patients receiving NOACs with different subgroups of warfarin-treated patients according to the time in therapeutic range, and it has been shown that the magnitude of the benefit of the NOACs compared with standard treatment is dependent on the quality of control of warfarin. 43 Third, the results of our meta-analysis are driven mainly by 3 large RCTs involving dabigatran, 8 rivaroxaban, 9 and apixaban, 10 whereas fewer data are available on edoxaban because the phase III RCT is currently ongoing. Fourth, the funnel plot for stroke or SE was asymmetrical with a lack of studies on the right part of the plot, suggesting that unpublished studies likely to demonstrate an increased risk of stroke or SE with NOACs were not included in our meta-analysis. Instead, the funnel plot for MI was lacking studies on the left side of the plot, suggesting that studies demonstrating a reduction in the risk of MI with NOACs were not included. However, because we performed an extensive research of the literature, including abstracts presented at congresses of several international societies, and because we contacted pharmaceutical companies asking for unpublished trials, the existence of other trials not included in our systematic review is extremely unlikely.
Conclusions
NOACs reduced overall and cardiovascular mortality, stroke and SE, and MB and intracranial bleeding compared with warfarin. These favorable efficacy and safety profiles now need to be confirmed in postmarketing studies.
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